Podcast: Anti-HIV vagina ring limited by cost, access

Season 4, Episode 44

The dapivirine vaginal ring holds promise in the fight against HIV. But for the young women in Africa who need it most, access remains a major challenge.

Women aged 15 to 24 are disproportionately vulnerable to HIV infection due to a complex web of factors, including social, cultural, and economic forces.

The silicone ring reduces their risk of infection by continually releasing the antiretroviral dapivirine into the vagina.

In this episode of Africa Science Focus, reporter Bunmi Yekini looks at issues such as access to the ring and the impact the ring has in countries that have approved its use.

Akhona Gxarisa, a research participant in the dapivirine study in South Africa, shares her experience of using the ring with her partner and advocates for greater availability of the product.

Patriciah Jeckonia, programme manager, policy and partnerships, at LVCT health, a non-governmental organisation in Kenya, says that the ring presents “an opportunity for women to prevent HIV and choose what works for them when they are at risk”.

In South Africa, the HIV prevention project FastPrEP is raising awareness of prevention methods among South African youths. Marketing and communications coordinator Mbali Jonas explains how this is being done, using mobile clinics and courier services.

Nigeria is one country that is yet to introduce the ring. Oliver Ezechi, director of research at the Nigerian Institute of Medical Research and professor of maternal, reproductive and child health at Lead City University, in Nigeria, explains why.

Do you have any comments, questions or feedback about our podcast episodes? Let us know at [email protected]

Africa Science Focus is produced by SciDev.Net and distributed in association with your local radio station

This piece was produced by SciDev.Net’s Sub-Saharan Africa English desk.